Literature DB >> 26880310

[Denosumab: Lifetime treatment of osteoporosis?].

Michel Laroche1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26880310     DOI： 10.1016/j.lpm.2015.12.010

Source DB:  PubMed          Journal:  Presse Med        ISSN： 0755-4982            Impact factor:   1.228


× No keyword cloud information.
  2 in total

1.  Ibandronate sodium and zoledronate sodium in the treatment of senile osteoporosis: efficacy, impact on quality of life and cost-effectiveness analysis.

Authors:  Shuang Liang; Shaozhen Hu; Hong Guo; Leilei Dong; Guoqiang Liu; Yang Liu
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

2.  Effect of risedronate on bone loss at discontinuation of denosumab.

Authors:  Michel Laroche; Guillaume Couture; Adeline Ruyssen-Witrand; Arnaud Constantin; Yannick Degboé
Journal:  Bone Rep       Date:  2020-06-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.